Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04013555 · ClinicalTrials.gov registry record · Phase 1
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT04013555 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 88 participants.
The verdict
NCT04013555, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine. One way to reliably increase KYNA levels is by ingesting the amino acid tryptophan. Tryptophan is a normal part of the human diet. Tryptophan gets metabolized/changed to other chemicals in the body- including KYNA. By giving people 6 grams of tryptophan, the investigators will be able to increase the KYNA level in a controlled way. The investigators will then be able to study the effects of KYNA on neurotransmitters by using cognitive tests and magnetic resonance imaging techniques (measuring brain activity and brain chemistry using the MRI magnet). The overall goal of the study is to examine how the medication N-acetylcysteine (NAC), when added to tryptophan, affects various cognitive functions, such as verbal and visual memory. The investigators will also use magnetic resonance imaging (MRI) to examine how NAC affects brain activity and chemicals.
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine (NAC)
- DRUG Tryptophan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2020-01-20 |
| Est. Completion | 2024-08-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04013555
The ClinicalTrials.gov registry entry for NCT04013555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04013555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04013555 about?
NCT04013555 is a clinical study titled "The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia". Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine. One way to reliably increase KYNA levels is by ingesting the amino acid tryptophan. Tryptophan is a normal part o...
What is the current status of trial NCT04013555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2020-01-20. Estimated completion is 2024-08-14.
What interventions are being tested in trial NCT04013555?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (NAC) (DRUG), Tryptophan (DRUG).
Who is sponsoring clinical trial NCT04013555?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.